OCEANIA CRUISES® ANNOUNCES ITS 2027 AROUND THE WORLD CRUISE ABOARD LUXURIOUS VISTA™
MIAMI, March 12, 2025 /PRNewswire/ -- Oceania Cruises ®, the world's leading culinary- and destination-focused cruise line, is redefining luxury global exploration with its 2027 Around the World cruise. The highly anticipated voyage will span 180 days, visiting more than 100 ports across 46 countries and six continents aboard one of the line's newest ships, Vista. Bookings for this once-in-a-lifetime voyage are available beginning March 12.
Setting sail from Miami on January 6, 2027, the 1,200-guest ship will embark on a transformative journey offering a carefully crafted itinerary that fosters enriching connections to diverse cultures, history, landscapes, and cuisine. Over the course of the six adventure-filled months, guests can explore more than 150 UNESCO World Heritage sites, inviting them to discover renowned cultural and natural wonders across the globe.
Guests will transit the Panama Canal, island-hop through the Pacific from Hawaii to Fiji and sail along Australia's stunning coastline. More than two months in Asia will unveil Thailand's golden temples, Hong Kong's vibrant markets, and Japan's cherry blossoms. After exploring the modern cities of the Arabian Peninsula, Vista will cruise the Mediterranean from Greece and Italy to the Iberian Peninsula and beyond to France before concluding her global trek in London.
Two additional itineraries are also available: a 244-day Epic Global Adventure from Miami to New York, our longest option ever offered on a world cruise, and the shorter 127-day Continental Explorer sailing from Miami to Doha.
'Our Around the World cruise is an incredible way to explore the world in style, elegance, and comfort, and we're thrilled to offer this immersive journey in 2027 aboard Vista,' said Jason Montague, Chief Luxury Officer, Oceania Cruises. 'Spanning six months at sea, this extraordinary voyage offers the rare opportunity to circumnavigate the globe while seamlessly connecting diverse continents, rich cultures, and authentic cuisines, creating an unforgettable experience for our guests.'
Starting at $76,199 per person, Oceania Cruises' 2027 Around the World sailing features the Exclusive Prestige Package, a generous array of additional complimentary amenities, including a choice of Free Unlimited Wine, Beer, and Spirits or a generous Shore Excursion Credit, plus Exclusive Shoreside Events, a Free Visa Package and Free Luggage Delivery. These extra inclusions sit alongside the line's Your World Included™ amenities, which include all gourmet specialty dining, in-stateroom dining, unlimited Starlink® WiFi, and shipboard gratuities.
Shipboard Highlights of Vista
An epic journey calls for an equally exceptional ship, and Vista delivers with unmatched elegance.
The 1,200-guest ship offers all-veranda accommodations, featuring the most spacious standard staterooms at sea, at an astounding 291 square feet.
Vista boasts a market-leading staffing ratio of two crew members for every three guests, ensuring an unparalleled level of warm, personalized service.
One chef for every 10 guests, meaning half of the onboard crew is dedicated to culinary experiences.
From immersive Culinary Discovery Tours™ ashore to hands-on cooking classes on board in The Culinary Center, guests can savor the flavors of the world and learn new skills as they sail.
Vista features 11 exceptional dining venues, including Aquamar® Kitchen, serving wellness-inspired dishes, The Bakery at Baristas, the classic Polo Grill Steakhouse, Italian Toscana, pan-Asian Red Ginger, and the elegant French restaurant Jacques.
Vista offers an elegant onboard experience with eight sophisticated bars, lounges, and entertainment venues.
Guests can unwind at the Aquamar® Spa + Vitality Center and its serene Aquamar® Spa Terrace, ensuring every moment at sea is as enriching as the destinations themselves.
Thousands of immersive small-group shore excursions and tours to choose from in destinations across the globe, offering the opportunity to see destinations through a new lens, whether the focus is food, wine, art, history, or architectural design.
Diverting onboard enrichment, including art classes at Oceania Cruises' much-loved Artist Loft and numerous guest speakers.
Food and wine pairing experiences, including demonstrations during exclusive Sommelier's Choice and Cellar Master's Classic Wine Pairing Luncheons.
For additional information on Oceania Cruises' small-ship luxury, exquisitely crafted cuisine, and expertly refined travel experiences, visit OceaniaCruises.com, call 855-OCEANIA, or speak with a professional travel advisor.
About Oceania Cruises
Oceania Cruises® is the world's leading culinary- and destination-focused cruise line. The line's eight small, luxurious ships carry a maximum of 1,250 guests and feature The Finest Cuisine at Sea® and destination-rich itineraries that span the globe. Expertly curated travel experiences are available aboard the designer-inspired, small ships, which call on more than 600 marquee and boutique ports in more than 100 countries on seven continents, on voyages that range from seven to more than 200 days. Oceania Cruises® has two additional ships on order scheduled for delivery in 2027 and 2028 or 2029 [1]. Oceania Cruises® is a wholly owned subsidiary of Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH). To learn more, visit www.nclhltd.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
44 minutes ago
- Business Upturn
Alcon Underscores Benefits of Its IOLs and Cataract Surgical Equipment at APACRS
By Business Wire India Published on August 19, 2025, 10:38 IST Business Wire India Data on Alcon's products across cataract, refractive, diagnostics and ocular health will be featured in presentations during the meeting Prospective analyses and studies demonstrate sustained performance of Vivity including in patients with common mild comorbidities Alcon's Symposia on new generation phaco and vitrectomy system will discuss new data on anterior chamber stability during cataract surgery performed at more physiologic IOP Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced a strong presence at the 37th Asia-Pacific Association of Cataract and Refractive Surgeons (APACRS) Annual Meeting. APACRS will be held at Mahatma Mandir Convention and Exhibition Centre (MMCEC) in Ahmedabad, India from August 21-23, 2025. The company will showcase four symposia, lead 10 medical affairs scientific exchange presentations, and offer a hands-on experience zone at booth #A1). These comprehensive activities combined with new data underscore Alcon's commitment to generating meaningful scientific evidence on the safety and efficacy of its innovations. Massimo Cerrone, Vice President, Surgical for Alcon Asia Pacific, said, 'APACRS brings together leading experts and their insights from across the region, creating an ideal environment to engage in critical topics such as the evolving needs of cataract care in the ageing population. Through a dynamic agenda, surgeons can explore Alcon's latest innovations and their value through clinical evidence, real-world insights, and peer experience across Asia-Pacific.' Key data being presented at this year's event Alcon's Vivity ® is an extensively studied Extended Depth of Focus (EDOF) intraocular lens (IOL) in special populations with different co-morbidities, supported by over 10 clinical studies involving more than 700 patients. Among these is a prospective study titled, ' To Evaluate The Visual Outcomes and Patient Satisfaction After Bilateral Vivity ® IOL Implantation in Patients with Mild Irregular Astigmatism.' Conducted by Dr. Ashvin Agarwal, analyses reinforce patient satisfaction outcomes with Vivity in this specific cohort. This will be shared as an e-poster. is an extensively studied Extended Depth of Focus (EDOF) intraocular lens (IOL) in special populations with different co-morbidities, supported by over 10 clinical studies involving more than 700 patients. Among these is a prospective study titled, ' Conducted by Dr. Ashvin Agarwal, analyses reinforce patient satisfaction outcomes with Vivity in this specific cohort. This will be shared as an e-poster. On the cataract equipment side, Dr. Shail Vasavada of Raghudeep Eye Hospital, will present a prospective, randomized, single masked, single-center study titled, 'Retinal Perfusion During Cataract Surgery With Varying Intraocular Pressure in Comorbid Eyes.' Data underlines the benefits of performing cataract surgery at more physiologic IOP in patients with diabetic retinopathy. (Friday, 22 August 2025, 15:20pm-15:25pm, at FP3-15, Seminar Hall 2, MMCEC) Amar Vyas, Country Head, Alcon India said, 'We are excited that India is hosting APACRS for the second time. The event is an ideal platform to showcase our breakthrough technologies like the Advanced Technology IOL portfolio and UNITY VCS/CS, and foster meaningful exchange amongst ECPs. As cataract procedures rise, it's critical that advanced technologies are both clinically proven across diverse patient populations and accessible to those who need them. We remain committed to empowering surgeons with science-backed solutions that elevate surgical precision and patient outcomes.' During the meeting, Alcon will host four symposia; interested participants can learn more and register at Alcon UNITY ® VCS Launch Symposium – Ready to explore the future of Surgical Innovation? Experience Superior Efficiency – Unity ® VCS, held exclusively for India on Thursday, 21 August 2025, 12:45pm to 13:40pm IST at Seminar Hall 2, Ground Floor. This session will mark the official introduction of UNITY VCS (Vitreoretinal Cataract System) and UNITY CS (Cataract System), Alcon's next-generation Phaco/Vit platform, to the Indian market. on Thursday, 21 August 2025, 12:45pm to 13:40pm IST at Seminar Hall 2, Ground Floor. This session will mark the official introduction of UNITY VCS (Vitreoretinal Cataract System) and UNITY CS (Cataract System), Alcon's next-generation Phaco/Vit platform, to the Indian market. Alcon IOL Symposium – Stay Ahead with the Clareon ® Collection on Friday, 22 August 2025,12:30pm to 13:25pm IST at Convention Hall 2, Ground Floor. This session will cover the Clareon Collection as a comprehensive IOL portfolio, discuss optical differentiation and performance of newer EDOF IOLs, and highlight the role of digital image guidance in toric correction. on Friday, 22 August 2025,12:30pm to 13:25pm IST at Convention Hall 2, Ground Floor. This session will cover the Clareon Collection as a comprehensive IOL portfolio, discuss optical differentiation and performance of newer EDOF IOLs, and highlight the role of digital image guidance in toric correction. Alcon Surgical Video Symposium – Experience Extraordinary Phaco & VR Surgery with the NEW UNITY ® VCS by Alcon on Saturday, 23 August 2025, 12:00pm to 12:55pm IST at Convention Hall 2, Ground Floor. Through live discussion and videos, leading surgeons will showcase their experience with UNITY VCS in cataract and vitreoretinal procedures. on Saturday, 23 August 2025, 12:00pm to 12:55pm IST at Convention Hall 2, Ground Floor. Through live discussion and videos, leading surgeons will showcase their experience with UNITY VCS in cataract and vitreoretinal procedures. Alcon Global Medical Affairs symposium – Vivity IOL, A True EDOF IOL with Proven Real-World Performance on Saturday, 23 August 2025, 13:00pm to 14:00pm IST at Seminar Hall 2, Ground Floor. The session, moderated by Dr. Vaishali Vasavada, will review meaningful real-world evidence supporting the use of Vivity IOL in special populations. To reserve your seat, visit For information on Alcon's presence at APACRS 2025, including the symposia and exhibition taking place at booth #A1, please visit the company's event page. The site will be updated following the event with on-demand content, such as archives of the symposia. Join the conversation on social platforms with the hashtag #APACRS2025 #Alcon. About the AcrySof IQ Vivity IOL The Wavefront Shaping AcrySof® IQ Vivity Extended Vision Posterior Chamber Intraocular Lens Model DFT015 (referred to as AcrySof IQ Vivity IOL) is a UV-absorbing and blue light-filtering foldable intraocular lens (IOL). This IOL, compared to a monofocal IOL, provides an extended range of vision from distance to near without increasing the incidence of visual disturbances.1 About UNITY VCS and UNITY CS The UNITY VCS (Vitreoretinal Cataract System) console, when used with compatible devices, is indicated for use during anterior segment (i.e. phacoemulsification and removal of cataracts) and posterior segment (i.e. vitreoretinal) ophthalmic surgery. In addition, with the optional laser this system is indicated for photocoagulation (i.e. vitreoretinal and macular pathologies), iridotomy and trabeculoplasty procedures. The UNITY CS (Cataract System) console, when used with compatible devices, is indicated for use during anterior segment (i.e. phacoemulsification and removal of cataracts) ophthalmic surgery.2 About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at The content of this press release is intended for use by healthcare professionals only, including Registered Medical Practitioners, hospitals, or laboratories, and its use in any publication is subject to applicable local laws and regulations. References Acrysof IQ Vivity Extended Vision IOL Global Directions for Use [REF-22568] UNITY VCS and CS User Manual 2024 [REF-27652] Connect with us on: Facebook LinkedIn View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash Business Wire India, established in 2002, India's premier media distribution company ensures guaranteed media coverage through its network of 30+ cities and top news agencies.
Business Upturn
44 minutes ago
- Business Upturn
Coloplast A/S – Interim Financial Report, 9M 2024/25
By GlobeNewswire Published on August 19, 2025, 10:33 IST 2024/25 Interim financial results, 9M 2024/25 1 October 2024 – 30 June 2025 Coloplast delivered organic growth of 7% and an EBIT margin1 of 28% in Q3. Reported revenue in DKK grew 1% with negative impact from currencies and the Skin Care divestment. Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 4% and Interventional Urology 4%. Growth in Ostomy Care was driven by broad-based contribution across regions, except for China which delivered low-single digit growth, as expected. Growth in Continence Care was driven by continued strong contribution from the Luja™ portfolio. Voice and Respiratory Care growth was driven by continued good momentum in both Laryngectomy and Tracheostomy. Growth in Advanced Wound Dressings was -2%, driven primarily by a significant decline in China which was impacted by a preventative and voluntary product return of all Biatain® Adhesive foam dressings in the market. The product return is expected to have a negative revenue impact of around DKK 80 million in H2, of which around DKK 20 million impacted Q3. Kerecis grew 17%, with a 13% EBIT margin before PPA amortisation. Growth in the quarter was impacted by a slowdown in the out-patient setting due to the LCD postponement in April, causing a temporary market shift to high-priced products. Growth momentum in Q4 is expected to improve, with a good start to the quarter in July. Growth in Interventional Urology was driven by good momentum in the US Men's Health business, partly offset by continued negative impact from the product recall in Bladder Health and Surgery of around DKK -10 million in Q3. EBIT 1 was DKK 1,915 million, a 2% increase from last year. The EBIT margin 1,2 was 28%, against 27% last year. was DKK 1,915 million, a 2% increase from last year. The EBIT margin was 28%, against 27% last year. Changes to the Executive Leadership Team announced, to support the successful execution of the new company strategy towards 2030. 9M 2024/25 organic growth of 7% and EBIT margin1 of 27%. Reported revenue in DKK grew 4% to DKK 20,914 million. Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 9% and Interventional Urology 1%. EBIT 1 was DKK 5,718 million, a 4% increase from last year. The EBIT margin 1 was 27%, on par with last year 2 . was DKK 5,718 million, a 4% increase from last year. The EBIT margin was 27%, on par with last year . Adjusted3 net profit before special items was DKK 3,778 million, a DKK 15 million decrease from last year, negatively impacted by non-cash effect from net financial expenses. Adjusted3 diluted earnings per share (EPS) before special items decreased by 1% to DKK 16.76. Adjusted3 ROIC after tax before special items was 15%, on par with last year. FY 2024/25 guidance is unchanged with organic growth of around 7% and an EBIT margin before special items of 27-28%. Organic growth now includes the negative impact from the product return in Advanced Wound Dressings in China, partly offset by good momentum in the other business areas. Reported growth in DKK is now expected to be 3-4%, with around 2%-points negative impact from currencies and around 1.5%-points negative impact from the Skin Care divestment. The assumptions on the reported EBIT margin before special items are largely unchanged. Special items expectations are unchanged, around DKK 450 million. Expectations on capital expenditures and tax rate (ordinary and effective) are also unchanged. 'We deliver a third quarter as expected with 7% organic growth and an EBIT margin of 28%, maintaining our financial guidance for 2024/25. Our Q3 performance was driven by broad-based growth across our chronic care businesses, offsetting the challenges in China. I'm pleased to see the global Coloplast organisation continuing to deliver on our priorities and moving the business forward. The search for Coloplast's new CEO remains on track. I look forward to presenting our 2030 strategy at our Capital Markets Day on 2 September alongside the new Executive Leadership Team, announced today,' says interim CEO Lars Rasmussen. 1. before special items expenses of DKK 83 million in Q3 2024/25 and DKK 241 million in 9M 2024/25. 2. before special items expenses of DKK 36 million in Q3 2023/24 and DKK 70 million in 9M 2023/24. 3. Adjusted for the impact from the Kerecis IP transfer. Conference call Coloplast will host a conference call on Tuesday, 19 August 2025 at 11.00 CEST. The call is expected to last about one actively participate in the Q&A session please sign up ahead of the conference call on the link here to receive an e-mail with dial-in details: Register here Access the conference call webcast directly here: Coloplast – 9M 2024/25 conference call For further information, please contact Investors and analysts Anders Lonning-SkovgaardExecutive Vice President, CFO Tel. +45 4911 1111 Aleksandra DimovskaVice President, Investor RelationsTel. +45 4911 1800 / +45 4911 2458 Email: [email protected] Kristine Husted MunkSenior Manager, Investor RelationsTel. +45 4911 1800 / +45 4911 3266 Email: [email protected] Simone Dyrby HelvindSenior Manager, Investor RelationsTel. +45 4911 1800 / +45 4911 2981 Email: [email protected] Press and media Peter MønsterSr. Media Relations ManagerTel. +45 4911 2623 Email: [email protected] Address Coloplast A/SHoltedam 1DK-3050 HumlebaekDenmark Company reg. (CVR) no. 69749917 Website This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail. Coloplast was founded on passion, ambition, and commitment. We were born from a nurse's wish to help her sister and the skills of an engineer. Guided by empathy, our mission is to make life easier for people with intimate healthcare needs. Over decades, we have helped millions of people to live a more independent life and we continue to do so through innovative products and services. Globally, our business areas include Ostomy Care, Continence Care, Advanced Wound Care, Interventional Urology and Voice and Respiratory Care. The Coloplast logo is a registered trademark of Coloplast A/S. © 2025-08. All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark. Attachment 06_2025_9M_2024_25_Earnings_release Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
an hour ago
- Yahoo
Tigermed Receives MSCI ESG AAA Rating
HANGZHOU, China, Aug. 18, 2025 /PRNewswire/ -- Tigermed is proud to announce that it has been awarded an MSCI Environmental, Social, and Governance (ESG) Rating of AAA, the highest rating in the industry. This recognition underscores our commitment to excellence in ESG practices, positioning us as a leader in sustainable business performance. MSCI's AAA rating is reserved for companies that demonstrate superior ESG performance and strong resilience to long-term risks. It reflects Tigermed's consistent efforts to integrate ESG principles into our core operations and strategic decision-making. Environmental:Tigermed has set science-based targets for reducing greenhouse gas emissions, which have been validated by the Science Based Targets initiative (SBTi). The company has implemented a comprehensive environmental management system, improved monitoring of emissions and resource utilization, and adopted digital platforms and green office initiatives to promote environmental sustainability. Social:W has advanced its digital transformation and leveraged AI technologies to enhance clinical trial efficiency. In 2024, Tigermed invested 39.997 million yuan in employee training, with an average of 99.48 hours per employee. The company ensures gender equality, promotes workforce diversity, and supports the well-being of its employees. Through the Hangzhou Tigermed Foundation, it engages in various public welfare activities, including medical assistance, education support, and poverty alleviation, while also contributing to rural revitalization through consumption-based poverty reduction efforts. Corporate Governance:Tigermed has strengthened its ESG governance and compliance framework. The board of directors oversees all ESG-related matters, and the Compliance and ESG Committee is directly led by the General Manager and managed by the Chief Compliance Officer. ESG performance is incorporated into the General Manager's compensation structure. All employees receive 100% coverage of business ethics training, and new suppliers are required to sign the Supplier Code of Conduct upon onboarding, followed by regular assessments. Since receiving its first MSCI ESG rating in 2020, Tigermed has consistently improved its performance, moving from a baseline rating to AA in 2023 and now achieving AAA. This progress reflects our ongoing investment in talent development, safety and quality management, carbon reduction, and ethical business practices. This AAA rating marks a new milestone in our ESG journey. We will continue to strengthen our ESG governance framework, refine our management systems, and drive sustainable growth. As a company committed to "Serving Innovation, Building Health Together," we aim to deliver long-term value to our stakeholders while contributing to global health and well-being. About Tigermed Tigermed (Stock code: is a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry. With a broad portfolio of services and a promise of quality, from preclinical development to clinical trial to commercialization, we are collaborating with over 3,600 customers and committed to moving their development journey efficiently and cost-effectively. Tigermed currently represents a worldwide network of more than 180 locations with over 10,000 employees across Asia Pacific, Europe, North America, Latin America and Africa. We are devoted to building an integrated platform that enables the boundless possibilities for the healthcare industry, embracing challenges to fulfill our commitment to serving unmet patients' needs, and ultimately saving lives. Learn more at View original content to download multimedia: SOURCE Tigermed Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
